Some MMT-associated outcomes (i.e., response rates; survival rates) were evaluated regardless of the tumor type with high responses rates and good survival outcomes, such as Entrectinib in NTRK fusion-positive solid tumors, Vemurafenib in non-melanoma BRAF V600 cancers, or even immune checkpoint-inhibitors as Pembrolizumab in MSI-high tumors [13,14,15]. The gene discussed is BRAF; the disease is neoplasm.